Supercharged immune cells take on childhood cancers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Recipient procurement inclusion criteria * Diagnosis of high-risk solid tumors: Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, soft tissue sarcomas, osteosarcoma, adenocarcinoma, and esophageal carcinoma and renal cell carcinoma. * Refractory disease, residual detectable disease following conventional therapy or relapsed disease. * 6 months to 60 years of age at enrollment.\* * Karnofsky/Lansky score of ≥ 50%.\* * Absolute neutrophil count (ANC) greater than 500/µL. \* * Absolute lymphocyte count (ALC) greater than 1000/µL.\* * Bilirubin ≤ 2.5 mg/dL. \* * Aspartate aminotransferase (AST)/ Alanine transaminase (ALT) ≤ 5x the upper limit of normal for age. \* * Serum creatinine \< 1.0 mg/dL or 2 x the upper limit of normal for age (whichever is higher).\* * Pulse oximetry of \> 90% on room air.\* * Agree to use contraceptive measures during study protocol participation (when age appropriate).\* * LVEF \> 50% or LVSF \> 27 % if history of total body irradiation (TBI). * Patient or parent/guardian capable of providing informed consent. Exclusion Criteria: Recipient Procurement exclusion criteria * Patients with uncontrolled infections * Patients with active HIV * Current evidence of GVHD \> grade 2 or chronic GVHD manifestations: bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis. * Pregnant or lactating females * Prior immunotherapy with an investigational agent within the last 28 days prior to procurement Recipient Inclusion to administer cells: * Steroids less than 0.5 mg/kg/day prednisone (or equivalent). * Karnofsky/Lansky score of ≥ 50% %. * Bilirubin ≤ 2.5 mg/dL. * AST/ALT ≤ 5x the upper limit of normal for age. * Serum creatinine \< 1.0 mg/dL or 2x the upper limit of normal for age (whichever is higher). * Pulse oximetry of \> 90% on room air. * Patients receiving lymphodepleting chemotherapy must have: ANC \>750 /uL Platelet count \>75,000 /uL Recipient Exclusion to administer cells: * Patients with uncontrolled infections * Patients who received ATG, Campath, or other T cell immunosuppressive monoclonal antibodies within 28 days prior to TAA-T cell infusion * Acute GVHD \> grade 2 or chronic GVHD manifestations: bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis * Pregnant or lactating females